Oramed Pharmaceuticals (NASDAQ:ORMP) Lifted to “Buy” at StockNews.com

StockNews.com upgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a buy rating in a report issued on Tuesday.

Separately, HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.

Oramed Pharmaceuticals Price Performance

Shares of NASDAQ:ORMP opened at $2.37 on Tuesday. The stock has a market capitalization of $96.42 million, a P/E ratio of 4.64 and a beta of 1.77. The business has a 50-day moving average of $2.40 and a two-hundred day moving average of $2.39. Oramed Pharmaceuticals has a fifty-two week low of $1.67 and a fifty-two week high of $3.67.

Oramed Pharmaceuticals (NASDAQ:ORMP) last announced its earnings results on Wednesday, August 14th. The biotechnology company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.01 by $0.21. As a group, research analysts expect that Oramed Pharmaceuticals will post 0.24 EPS for the current fiscal year.

Institutional Trading of Oramed Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Murchinson Ltd. boosted its stake in Oramed Pharmaceuticals by 23.2% during the second quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock worth $4,369,000 after buying an additional 320,495 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Oramed Pharmaceuticals during the 1st quarter valued at about $68,000. Dimensional Fund Advisors LP boosted its position in shares of Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after acquiring an additional 10,774 shares in the last quarter. XTX Topco Ltd bought a new stake in Oramed Pharmaceuticals in the second quarter valued at about $40,000. Finally, Renaissance Technologies LLC raised its position in Oramed Pharmaceuticals by 89.0% in the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 108,700 shares in the last quarter. Institutional investors and hedge funds own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.